RA Capital Launches Structured Capital Solutions
RA Capital Management, a leading healthcare-focused investment firm, has expanded its capabilities to include structured capital solutions. The firm has brought on Jeremy Lack and Adam Kaye as Senior Managing Directors and Partners to lead this new strategy. This expansion allows RA Capital to offer a comprehensive suite of equity, debt, royalty, and hybrid financing solutions for commercial stage companies in the healthcare and life sciences sectors.
The structured capital team will leverage RA Capital's existing platform, including its TechAtlas research division, to provide creative financing options for innovative companies. This move enables RA Capital to support companies throughout their growth stages, from early development to commercialization. The firm aims to partner with leading companies in pharmaceuticals, biotech, medical products, healthcare services, research tools, and HCIT sub-sectors.
RA Capital Management, una delle principali società di investimento focalizzate sulla sanità, ha ampliato le proprie capacità per includere soluzioni di capitale strutturate. La società ha reclutato Jeremy Lack e Adam Kaye come Direttori Previdenti e Partner per guidare questa nuova strategia. Questa espansione consente a RA Capital di offrire un ampio pacchetto di soluzioni di finanziamento in equità, debito, royalties e ibride per aziende in fase commerciale nei settori della sanità e delle scienze della vita.
Il team di capitale strutturato sfrutterà la piattaforma esistente di RA Capital, inclusa la sua divisione di ricerca TechAtlas, per fornire opzioni di finanziamento creative per aziende innovative. Questa mossa permette a RA Capital di sostenere le aziende durante le loro fasi di crescita, dallo sviluppo iniziale alla commercializzazione. La société intende collaborare con aziende leader nei settori farmaceutico, biotecnologico, prodotti medicali, servizi sanitari, strumenti di ricerca e sotto-settori HCIT.
RA Capital Management, una firma de inversión líder enfocada en la atención médica, ha ampliado sus capacidades para incluir soluciones de capital estructurado. La firma ha incorporado a Jeremy Lack y Adam Kaye como Directores Generales y Socios para liderar esta nueva estrategia. Esta expansión permite a RA Capital ofrecer un conjunto integral de soluciones de financiamiento en equidad, deuda, regalías e híbrido para empresas en etapa comercial en los sectores de atención médica y ciencias de la vida.
El equipo de capital estructurado aprovechará la plataforma existente de RA Capital, incluida su división de investigación TechAtlas, para proporcionar opciones de financiamiento creativas para empresas innovadoras. Este movimiento permite a RA Capital apoyar a las empresas en todas las etapas de su crecimiento, desde el desarrollo temprano hasta la comercialización. La firma tiene como objetivo asociarse con empresas líderes en los sectores de farmacéuticos, biotecnología, productos médicos, servicios de salud, herramientas de investigación y subsectores de HCIT.
RA Capital Management는 의료에 중점을 둔 주요 투자 회사로서 구조화된 자본 솔루션을 포함하도록 역량을 확장했습니다. 이 회사는 이 새로운 전략을 이끌기 위해 Jeremy Lack와 Adam Kaye를 선임 관리 이사 및 파트너로 모셨습니다. 이번 확장은 RA Capital이 의료 및 생명과학 분야의 상업적 단계에 있는 기업을 위해 주식, 부채, 로열티 및 하이브리드 금융 솔루션의 포괄적 패키지를 제공할 수 있게 합니다.
구조화된 자본 팀은 혁신적인 기업을 위해 창의적인 금융 옵션을 제공하기 위해 RA Capital의 기존 플랫폼, 특히 TechAtlas 연구 부서를 활용할 것입니다. 이 조치는 RA Capital이 초기 개발에서 상업화까지 기업의 성장 단계 전반에 걸쳐 지원할 수 있게 합니다. 이 회사는 제약, 생명공학, 의료 제품, 의료 서비스, 연구 도구 및 HCIT 하위 섹터의 선도적인 기업과 파트너 관계를 맺는 것을 목표로 합니다.
RA Capital Management, une société de gestion d'investissement leader axée sur la santé, a élargi ses capacités pour inclure des solutions de capital structuré. La société a recruté Jeremy Lack et Adam Kaye comme Directeurs Généraux Seniors et Associés pour diriger cette nouvelle stratégie. Cette expansion permet à RA Capital d'offrir un large éventail de solutions de financement par actions, dettes, redevances et hybrides pour des entreprises à stade commercial dans les secteurs de la santé et des sciences de la vie.
Le département de capital structuré tirera parti de la plateforme existante de RA Capital, y compris sa division de recherche TechAtlas, pour fournir des options de financement créatives aux entreprises innovantes. Cette mesure permet à RA Capital de soutenir les entreprises tout au long de leurs phases de croissance, du développement précoce à la commercialisation. La société vise à s'associer avec des entreprises leaders dans les domaines pharmaceutiques, biotechnologiques, de produits médicaux, de services de santé, d'outils de recherche et de sous-secteurs HCIT.
RA Capital Management, eine führende Investmentgesellschaft mit Fokus auf das Gesundheitswesen, hat ihre Fähigkeiten erweitert, um strukturierte Kapitallösungen anzubieten. Das Unternehmen hat Jeremy Lack und Adam Kaye als Senior Managing Directors und Partner verpflichtet, um diese neue Strategie zu leiten. Diese Erweiterung ermöglicht es RA Capital, ein umfassendes Angebot an Eigenkapital-, Fremdkapital-, Lizenz- und hybriden Finanzierungslösungen für Unternehmen in der kommerziellen Phase in den Bereichen Gesundheitswesen und Lebenswissenschaften anzubieten.
Das Team für strukturierte Kapitallösungen wird die bestehende Plattform von RA Capital nutzen, einschließlich der Forschungsabteilung TechAtlas, um kreative Finanzierungsmöglichkeiten für innovative Unternehmen bereitzustellen. Dieser Schritt ermöglicht es RA Capital, Unternehmen in allen Wachstumsphasen zu unterstützen, von der frühen Entwicklung bis zur Kommerzialisierung. Das Unternehmen zielt darauf ab, Partnerschaften mit führenden Unternehmen in den Bereichen Pharmazeutika, Biotechnologie, medizinische Produkte, Gesundheitsdienstleistungen, Forschungswerkzeuge und HCIT-Subsektoren einzugehen.
- Expansion of RA Capital's investment capabilities to include structured capital solutions
- Addition of experienced industry veterans Jeremy Lack and Adam Kaye to lead the new strategy
- Ability to offer comprehensive financing solutions across the capital stack for commercial stage companies
- Leveraging existing TechAtlas research division for informed investment decisions
- Potential to support a broader range of companies in various healthcare and life sciences sub-sectors
- None.
Insights
RA Capital's expansion into structured capital solutions marks a significant strategic move in the healthcare investment landscape. This diversification allows RA Capital to offer a full spectrum of financing options, potentially increasing its
The addition of industry veterans Jeremy Lack and Adam Kaye brings valuable expertise in credit and structured capital, which could lead to more sophisticated deal structures and potentially higher returns. This move may also help RA Capital retain clients as they transition from development to commercialization stages, ensuring a continuous revenue stream.
However, entering the structured capital space also exposes RA Capital to new risks, including potential conflicts of interest between equity and debt positions. Investors should monitor how effectively RA Capital manages these challenges while capitalizing on the expanded market opportunities.
RA Capital's new structured capital solutions represent a timely response to the evolving needs of the healthcare sector. As more companies transition from R&D to commercialization, there's an increasing demand for flexible financing options beyond traditional equity.
This move positions RA Capital to capitalize on the growing trend of complex financing structures in healthcare, particularly for commercial-stage companies. The firm's ability to offer tailored solutions across the capital stack could be a significant competitive advantage, potentially attracting a broader range of clients and deals.
The integration of structured capital with RA Capital's existing TechAtlas research division could lead to more informed investment decisions and potentially higher success rates in backing innovative healthcare companies. This holistic approach may set a new standard in healthcare investing, benefiting both investors and the broader healthcare ecosystem.
Leading Healthcare-Focused Investor Expands Capabilities to Provide Comprehensive Suite of Equity, Debt, Royalty, and Hybrid Financing Solutions for Commercial Stage Companies
Industry Veterans Jeremy Lack and Adam Kaye to Lead New Strategy
With deep industry and sector expertise and an evidence-based investment approach, RA Capital has a 20-year track record of successfully helping healthcare and life sciences companies create value and advance their objectives. Augmenting RA Capital's platform with structured capital solutions expands the firm's capabilities to more effectively meet the changing capital needs of private and public companies in the space through flexible equity, debt, royalty, and hybrid solutions. The structured capital strategy will benefit from the full RA Capital platform – including TechAtlas, the firm's research division, and its scientifically trained team – to structure a comprehensive suite of creative financing solutions for innovative, best-in-class companies.
"Over time, we've had the good fortune to see some of the development-stage companies we've supported with equity move on from simpler financials towards commercialization of their products, making them credit eligible. What held us back from expanding into credit and structured capital investments was knowing it takes a particular expertise we didn't have to design and negotiate these instruments," said Peter Kolchinsky, Founder and Managing Partner at RA Capital. "Now, with Jeremy and Adam joining, we can finally offer the full range of capital to help healthcare companies grow. It's gratifying to be able to provide the right kind of capital to a broader range of companies, both the ones we already fund with equity as well as many others we admire. With all the innovation in medicines, devices, diagnostics, healthcare services, and research tools, we are optimistic about the potential for investors and non-investors alike."
RA Capital's structured capital solutions team will partner with commercial stage companies spanning the pharmaceutical, biotech, medical products, healthcare services, research tools, and HCIT sub-sectors to provide holistic and bespoke financing solutions across the capital stack. Partnering with leading companies to support their growth, the structured solutions team will provide financing for enhanced capabilities and infrastructure, research and development, and acquisition opportunities.
"It is an exciting time to be a healthcare investor as we continue to see more innovative products and services reach the market," said Dr. Lack. "Adam and I are thrilled to join RA Capital, a firm with high-connectivity and expertise across the entire healthcare ecosystem, to work with leading companies and management teams to develop creative capital solutions. With the addition of structured capital solutions to its platform, RA Capital will be well positioned to continue funding companies as they mature and bring lifesaving services and therapies to patients."
"RA Capital has evolved into a leading healthcare and life science firm with extensive capabilities and a long history of delivering extraordinary results," said Mr. Kaye. "We believe that structured capital solutions offer an attractive financing option for many healthcare and life sciences companies, making RA Capital a full-service platform with an integrated set of creative financing options, throughout the entire capital structure."
About Jeremy Lack
Dr. Lack has broad investment experience in the healthcare sector across a diverse range of asset classes, geographies, and transaction types. Previously, he was a Partner and President at Athyrium Capital Management, a Managing Director at the Cortec Group, and a Principal at New Leaf Venture Partners. Dr. Lack also founded and led Durata Therapeutics (NASDAQ: DRTX), a spin-out from Pfizer that focused on antibiotics and was later acquired by Actavis. Earlier in his career, Dr. Lack was a consultant at McKinsey & Company and served as the Director of Strategic Planning for the New York City Department of Education. Dr. Lack earned a D.Phil. in Biochemistry from the University of Oxford, where he was a Marshall Scholar, and a B.S. with honors from the School of Industrial and Labor Relations at Cornell University.
About Adam Kaye
Mr. Kaye spent the last 20 years working across credit and equity financing, most recently serving as a Managing Director at Sixth Street. Prior to Sixth Street, Mr. Kaye was a Managing Director at Hayfin Capital Management and previously worked at New Health Capital Partners and New Leaf Venture Partners. Earlier in his career, Mr. Kaye was a healthcare investment banker at ThinkEquity Partners and BMO Capital Markets. He earned an M.S. in Biology from
About RA Capital
Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our TechAtlas internal research division, and Raven, RA Capital's company creation team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 150 employees and over
View original content to download multimedia:https://www.prnewswire.com/news-releases/ra-capital-launches-structured-capital-solutions-302250979.html
SOURCE RA Capital Management, LP
FAQ
What new investment capabilities has RA Capital Management added?
Who are the new leaders of RA Capital's structured capital solutions team?
How will RA Capital's structured capital solutions benefit companies?
What is Jeremy Lack's background in relation to DRTX?
